{"denoms":[{"counts":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"159"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG000","title":"Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort"},{"description":"Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG001","title":"Locally Advanced Unresectable cSCC Cohort"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.3","value":"70.0"},{"groupId":"BG001","spread":"12.4","value":"73.7"},{"groupId":"BG002","spread":"13.8","value":"71.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"40"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"119"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"15"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"97"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"47"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"108"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"44"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The analysis population consisted of all participants who received ≥1 dose of study treatment."}